NCT06797817 · Phase 3 · NOT YET RECRUITING
Tributyrin Treatment in Mild Alzheimer Disease: Assessment of Butyrate Effects Via the Gut-Brain
This trial is testing tributyrin, a dietary supplement that the body converts to butyrate, a compound produced by gut bacteria. Researchers want to know whether it can slow cognitive decline and reduce inflammation in people with mild Alzheimer's disease. They will also track gut health and blood markers like pTau217 and NfL. It is a Phase 3 trial, meaning it is a larger, later-stage test of whether the approach actually works.
You may qualify if
- individuals diagnosed with mild AD within the past year (ICD-10: F00.1).
- voluntary consent to participate in the study in accordance with the Declaration of Helsinki.
- not currently enrolled in any other clinical trial that could confound the results.
You're excluded if
- individuals with other potential causes of dementia, such as a history of severe traumatic brain injury, brain tumours, epilepsy, or central nervous system infections.
- individuals involved in an intervention that interferes with the trial (immunosuppressive drugs, steroids, antibiotics, or received chemotherapy in the month prior to the start of the intervention).
- individuals with gastrointestinal disorders.
The sponsor's own eligibility wording, lightly reformatted. The study team makes the final eligibility decision — worth discussing with your doctor.
Eligibility criteria as of 2025-12-18